Alberico L. Catapano (Italy)

University of Milan and IRCCS Multimedica Department of Pharmacological and Biomolecular Sciences
Alberico Catapano is Full Professor of Pharmacology, Director of the Centre of Epidemiology and Preventive Pharmacology (SEFAP) as well as Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis at the University of Milan (Department of Pharmacological and Biomolecular Sciences) and PhD coordinator from 2017 to 2020. Moreover, he is Director of the Centre for the Study, Prevention and Therapy of Atherosclerosis of the University of Milan, at the Bassini Hospital, Head of Cardiovascular Research Line at Multimedica IRCCS Sesto San Giovanni (Mi), President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation. His main research interests, from 1972, include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information. Past President of the European Atherosclerosis Society (EAS), Professor Catapano is currently Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias. Editor of Atherosclerosis Supplements, Co-editor of Atherosclerosis and Associate Editor of other scientific journals, he has authored more than 500 scientific papers in peer-reviewed journals (I.F. 7.071) and is among the highly cited scientists in 2019 and 2020 according to Clarivate.

Author Of 20 Presentations

Introduction 3 (ID 1610)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:03 - 15:04

Session close (ID 1560)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:29 - 10:30

Live Q&A (ID 1390)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:20 - 15:45

Introduction 2 (ID 1619)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:37 - 16:38

Live Q&A (ID 1572)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
17:20 - 17:30

Introduction (ID 1529)

Session Type
Plenary Session
Session Name
Session Time
12:30 - 13:00
Date
Wed, 02.06.2021
Room
Hall C
Lecture Time
12:30 - 12:33

Introduction 4 (ID 1621)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
17:19 - 17:20

Introduction 1 (ID 1577)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:15 - 16:17

Panel discussion (ID 1559)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:20 - 10:29

Live Q&A (ID 1370)

Introduction 4 (ID 1611)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:19 - 15:20

Welcome and introduction (ID 1563)

Session Type
Industry Sponsored Session
Session Time
12:30 - 13:15
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
12:30 - 12:33

Introduction 1 (ID 1525)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
14:30 - 14:32

Introduction 3 (ID 1620)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:58 - 16:59

Meet the experts - Targeting ANGPTL3- Game changer in lipid lowering? (ID 1573)

Session Type
Meet the experts
Session Time
17:00 - 17:30
Date
Tue, 01.06.2021
Room
Meet the expert session hall
Lecture Time
17:00 - 17:30

Welcome and introduction (ID 1554)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
09:45 - 09:48

O004 - Role of the Interleukin-1 Receptor/Toll Like Receptor TIR8/SIGIRR in experimental atherosclerosis (ID 1235)

Session Type
Late Breaking Sessions
Session Time
11:00 - 12:30
Date
Mon, 31.05.2021
Room
Hall A (Live Q&A)
Lecture Time
11:21 - 11:28

Abstract

Background and Aims

TIR8/SIGIRR dampens the excessive activation mediated by ILRs and TLRs agonism and thus is a key regulator of inflammation. Aim of this study was to investigate the role of TIR8 in atherosclerosis.

Methods

8 weeks old-LDLR KO and TIR8/LDLR double KO (DKO) male mice were fed with standard diet (STD) or cholesterol-enriched diet (WTD) for 12 weeks. Plasma lipid profiling, extensive immunophenotyping and histological analysis of the atherosclerotic plaques were then performed.

Results

TIR8 deletion in STD-fed LDLR KO mice impacts circulating immune cell profile: decreased percentage of T lymphocytes (-29%, p<0.001) and increased percentage of B cells (+14%, p<0.05) were observed compared to LDLR KO mice, as well as increased mature Natural Killer cells (+13%, p<0.0001), as already described in the TIR8 KO mouse model. When fed a cholesterol rich diet for 12 weeks to induce atherosclerosis, in addition to changes observed on STD, also circulating levels of monocytes increased in DKO mice compared to LDL-R KO mice (mean 1464 vs 910 cells/ul, p<0.05). These changes in immune profile, however, did not affect atherosclerotic plaque area or stability. Similarly, no differences in plasma lipid profile were observed.

Conclusions

TIR8 deficiency in LDLR KO mice increases NKs and monocytes blood levels compared to LDL-R KO mice. Changes in these immune subsets, however, do not impact the development of atherosclerosis.

Hide

O016 - Mendelian randomization mediation analysis of the direct and indirect effects of adiposity on coronary artery disease (ID 1136)

Session Type
Genetics
Session Time
15:00 - 16:30
Date
Mon, 31.05.2021
Room
Live Streamed
Lecture Time
16:05 - 16:13

Abstract

Background and Aims

Increased adiposity is associated with an increased risk of coronary artery disease (CAD). Whether adiposity has a direct causal effect on the risk of CAD, or whether the effect of adiposity on CAD is mediated indirectly through the effect of adiposity on other risk factors is unknown.

Methods

We constructed a body mass index (BMI) instrumental variable genetic score composed of 96 variants associated with BMI. We used this instrument to conduct a multivariable Mendelian randomization (MR) mediation analysis to estimate the direct and indirect effects of BMI on CAD. The study included individual level data on 445,774 participants including 23,032 cases of CAD and 28,563 cases of type II diabetes (T2D); and summary data on up to 877,643 participants including 63,746 cases of CAD and 26,676 cases of T2D.

Results

A one unit increase in BMI was associated with a 7% increased odds of CAD (OR:1.07; 95%CI:1.05-1.09, p=1.6E-10), a 25% increased odds of T2D (OR:1.25, 95%CI:1.23-1.28, p=2.2E-131); and 0.34 mmHg increase in systolic blood pressure (SBP) (95%CI:0.25-0.42, p=8.5E-15). A one unit increase in BMI was also associated with a 0.02 mmol/L increase in triglycerides (95%CI:0.02-0.03, p=4.9E-21), but not with increased apolipoprotein B levels. In MR mediation analyses, 80.0% of the effect of BMI on the risk of CAD was mediated through BMI induced increases in SBP (29.6%) and T2D risk (50.4%).

Conclusions

The vast majority of the effect of increased BMI on the risk of CAD appears to be mediated indirectly through the effect of BMI on SBP and T2D.

Hide

O023 - The low-density lipoprotein receptor (LDL-R) is an immune-metabolic checkpoint during CD8 T lymphocytes activation (ID 1251)

Session Type
Vascular Biology
Session Time
16:00 - 17:30
Date
Mon, 31.05.2021
Room
Hall E
Lecture Time
16:30 - 16:38

Abstract

Background and Aims

Activation of T lymphocytes combines functional to metabolic rewiring of cell machinery, including cholesterol homeostasis. Here we evaluated the role of LDLR on T cell biology

Methods

Immunophenotypic characterization of CD8T cells from WT and LDLR KO mice was performed in vitro (anti-CD3/CD28) and in vivo (vaccination, homeostatic proliferation) coupled to proteomic and confocal analysis on isolated CD8T cells. In parallel, T cells from FH were tested.

Results

LDLR deficiency dampened CD8+ proliferation (-35%, p<0.01) paralleled by a reduction in INFγ production (-39.6%, p<0.01). In vivo antigen-specific activation by ovalbumin vaccination, but not homeostatic proliferation, resulted in a decreased proliferation and cytokines production (↓IFNγ p<0.001,↓IL13 p<0.01,↓perforin p<0.05) in CD8+ of KO mice. Incubation with LDL significantly increased the proliferation in WT but not KO CD8T cells (+11%,p<0.01), a phenotype that was compensated by a reprogramming of de-novo synthesis in KO CD8T cells. Proteomic analysis revealed an impairment in glycolysis and OXPHOS associated to downregulation of pathways downstream to mTORC1 activation, possibly link to its reduced lysosomal localization observed in KO CD8T cells.

CD8+ T cells from FH subjects proliferated less (-36%, p>0.05) compared to sex- and age-matched controls and presented a decreased granzyme production (-60.3%, p<0.01) when CD8 memory response was tested in vitro with virus-derived peptides in seasonal influenza vaccinated matched controls and FH subjects.

Conclusions

LDLR plays a critical role in regulating the immunometabolic responses in CD8+ Tcells, and thus might represent a checkpoint linking cellular cholesterol metabolism to adaptive immune response.

Hide

O041 - PCSK9 deficiency and heart metabolism (ID 1014)

Session Type
Rapid Fire Session
Session Time
14:30 - 15:30
Date
Tue, 01.06.2021
Room
Hall F
Lecture Time
14:33 - 14:38

Abstract

Background and Aims

Increased lipoprotein receptor expression in the heart was associated with lipid accumulation, cardiomyocyte mitochondrial impairment and cardiac dysfunction. This project aimed at investigating whether PCSK9 regulates lipoprotein receptors expression in the heart, thus modulating heart metabolism and cardiac function.

Methods

Pcsk9 KO, Albumin CRE PCSK9LoxP/LoxP conditional KO) and double LDLr-Pcsk9 KO male mice undewent an extensive characterization for heart function followed by heart metabolomics and proteomic profiling.

Results

Pcsk9 KO hearts presented heart failure with preserved ejection fraction, reduced running resistance without muscular defects coupled to major adaptations in cardiac metabolism and mitochondrial functionality. This profile was associated with lipid accumulation in the heart. Moreover PCSK9 deficiency resulted in the accumulation of carnitine-conjugated fatty acid (C8; 0,066±0,047 Vs0,195±0,035 and C12; 0,021±0,018Vs0,11±0,069 pg/ug of prot, p<0,05) which was paralleled by a reduction of glucose 6-P, ribose-5P and erythrose-4P levels in the heart, suggesting a shift from fatty acid oxidation toward anaerobic glycolysis. Also Krebs cycle intermediates were reduced compared to WT samples. A similar phenotype was observed in LDLr Double KO confirming an effect independent of LDLr expression. The cardiac phenotype was reverted in the liver selective KO model thus excluding the involvement of circulating PCSK9 in the development of HFpEF observed in full KO mice. Translational studies showed that human subjects carrying the R46L loss of function polymorphism displayed increased left ventricular mass without alterations in ejection fraction compared to R46R BMI-matched controls.

Conclusions

These data suggest that PCSK9 deficiency impacts cardiac lipid metabolism indepedently of LDLR modulation and promotes the development of HFpEF.

Hide

Presenter of 16 Presentations

Welcome and introduction (ID 1554)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
09:45 - 09:48

Introduction 3 (ID 1610)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:03 - 15:04

Session close (ID 1560)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:29 - 10:30

Live Q&A (ID 1390)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:20 - 15:45

Introduction 2 (ID 1619)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:37 - 16:38

Live Q&A (ID 1572)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
17:20 - 17:30

Introduction (ID 1529)

Session Type
Plenary Session
Session Name
Session Time
12:30 - 13:00
Date
Wed, 02.06.2021
Room
Hall C
Lecture Time
12:30 - 12:33

Introduction 4 (ID 1621)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
17:19 - 17:20

Introduction 1 (ID 1577)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:15 - 16:17

Panel discussion (ID 1559)

Session Type
Industry Sponsored Session
Session Time
09:45 - 10:30
Date
Sun, 30.05.2021
Room
Industry session hall
Lecture Time
10:20 - 10:29

Live Q&A (ID 1370)

Introduction 4 (ID 1611)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
15:19 - 15:20

Welcome and introduction (ID 1563)

Session Type
Industry Sponsored Session
Session Time
12:30 - 13:15
Date
Mon, 31.05.2021
Room
Industry session hall
Lecture Time
12:30 - 12:33

Introduction 1 (ID 1525)

Session Type
CME Session
Session Time
14:30 - 15:45
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
14:30 - 14:32

Introduction 3 (ID 1620)

Session Type
CME Session
Session Time
16:15 - 17:30
Date
Sun, 30.05.2021
Room
Hall A (Live Q&A)
Lecture Time
16:58 - 16:59

Meet the experts - Targeting ANGPTL3- Game changer in lipid lowering? (ID 1573)

Session Type
Meet the experts
Session Time
17:00 - 17:30
Date
Tue, 01.06.2021
Room
Meet the expert session hall
Lecture Time
17:00 - 17:30

Moderator of 8 Sessions

Date
Tue, 01.06.2021
Session Time
17:00 - 17:30
Room
Meet the expert session hall
Date
Sun, 30.05.2021
Session Time
09:45 - 10:30
Room
Industry session hall
Date
Sun, 30.05.2021
Session Time
16:15 - 17:30
Room
Hall A (Live Q&A)

Meet the experts - Addressing residual risk beyond LDL-c in high or very high-risk patients (ID 55)

Date
Mon, 31.05.2021
Session Time
17:30 - 18:00
Room
Meet the expert session hall
Date
Mon, 31.05.2021
Session Time
12:30 - 13:15
Room
Industry session hall
Date
Wed, 02.06.2021
Session Time
12:30 - 13:00
Room
Hall C